Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study

Table 1 Percentage of simulations in which interruption of transmission occurred for different strategies and deploy times

Strategies	Interrupted transmission [%]
	PfPR_2–10 [%]
	2	4	5	7
3 years full MDA rounds	80	20	0	0
2 years full MDA rounds + vaccine	90	40	0	0
2 years full MDA rounds + vaccine	100^A	40^A	0^A	0^A
2 years full MDA rounds + longer duration vaccine	100	60	30	0
2 years full MDA rounds + longer duration vaccine	80^A	40^A	30^A	0^A
2 years full MDA rounds + vaccine lower efficacy	60	0	0	0
2 years full MDA rounds + vaccine lower efficacy	30^A	0^A	0^A	0^A
2 years full MDA rounds	20	0	0	0
2 years reduced MDA rounds + vaccine	70	10	0	0
2 years reduced MDA rounds + vaccine	70^A	0^A	0^A	0^A
2 years reduced MDA rounds + longer duration vaccine	90	70	0	0
2 years reduced MDA rounds + longer duration vaccine	80^A	10^A	0^A	0^A
2 years reduced MDA rounds + vaccine lower efficacy	30	0	0	0
2 years reduced MDA rounds + vaccine lower efficacy	30^A	0^A	0^A	0^A

Percentage of resurgence in the simulations are shown for interventions (rows) at 60% coverage, for 2- and 3- years of full rounds of MDA, and 2 years of full or reduced rounds of MDA combined with mass vaccination with RTS,S like vaccine (initial efficacy against infection 91%, half-life 0.61 years), longer duration of protection vaccine (half-life 1.5 years), or lower initial efficacy (50%). Results are shown for different levels of initial PfPR_2–10 (%) (columns), and results where the vaccine is given to same proportion of the population than the simultaneous MDA are indicated with ^A

ISSN: 1471-2334